Using machine learning to identify patients with cancer that would benefit from immunotherapy
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen.
Apr 16, 2024
0
0
A new study examines the development of two machine learning models to classify the immunophenotype of a cancer specimen.
Apr 16, 2024
0
0
Adjuvant alectinib improves disease-free survival compared with platinum-based chemotherapy among patients with resected ALK-positive non-small cell lung cancer (NSCLC), according to a study published in the April 11 issue ...
Apr 13, 2024
0
1
Cancer is a prevalent disorder where cells divide and grow uncontrollably and eventually spread to other regions or organs in the body. Non-small cell lung cancer (NSCLC) is a highly prevalent form of lung cancer. Current ...
Apr 2, 2024
0
0
Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced ...
Mar 27, 2024
0
0
A study published in the journal Science Bulletin was led by Yi-Long Wu (Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Chinese Thoracic Oncology Group (CTONG)).
Mar 5, 2024
0
0
For patients with advanced or metastatic non-small cell lung cancer (NSCLC) and limited performance status, an immune checkpoint inhibitor drug called durvalumab is safe and may benefit overall survival, according to a new ...
Nov 21, 2023
0
37
For patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), osimertinib with chemotherapy leads to significantly longer progression-free survival (PFS) compared with osimertinib alone, according to a study ...
Nov 16, 2023
0
1
More people with non-small cell lung cancer (NSCLC) are likely to benefit from new drugs that target molecular alterations in tumor cells, with less need for chemotherapy, following results of multiple clinical trials reported ...
Oct 18, 2023
0
0
Research findings from the CheckMate 227 trial will be presented at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2023 in Singapore, shedding light on the six-year survival ...
Sep 9, 2023
0
1
For patients with non-small cell lung cancer (NSCLC) ineligible for platinum-based chemotherapy, first-line atezolizumab monotherapy is associated with improved overall survival compared to single-agent chemotherapy, according ...
Aug 15, 2023
0
4